Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 5, 2005, Pages 3100-3105

  Sudhir, Krishnankutty ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; DNA POLYMORPHISM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; JAPAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; HUMANS; INFLAMMATION; PHOSPHOLIPASES A; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 18844433282     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2027     Document Type: Review

References (35)

1. Dada N, Kim NW, Wolfert RL 2002 Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diag 2:89-94
2. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19:2909-2917
3. 2 is highly expressed in macrophages of coronary lesions prone to rupture. Circulation 110(Suppl III):246-247
4. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150:413-419
5. 2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1:121-125
6. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338(Pt 2):479-487
7. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126
8. Quinn MT, Parthasarathy S, Steinberg D 1988 Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 85:2805-2809
9. 2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505:357-363
10. Tsaoussis V, Vakirtzi-Lemonias C 1994 The mouse plasma PAF acetylhydrolase: II. It consists of two enzymes both associated with the HDL. J Lipid Mediat Cell Signal 9:317-331
11. -/- mice. FASEB J 14:2032-2039
12. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P 2001 Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103:2495-2500
13. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD 2002 Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22:306-311
14. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD 2003 Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44:927-934
15. 2 (plateletactivating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14:347-352
16. Tselepis AD, Karabina S-A, Stengel D, Piédagnel R, Chapman MJ, Ninio E 2002 N-linked glycosylation of macrophage derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 2:1645-1654
17. 2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155
18. Ballantyne C, Hoogeveen R, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR 2004 Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and I women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109:837-842
19. 2 and risk of coronary events in apparently healthy middle-aged men with moderately elevated cholesterol. Results from the 14-year follow-up of the MONICA-Augsburg cohort 1984. Circulation 110:1903-1908
20. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111:570-575
21. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38:1302-1306
22. 2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis, in press
23. 2 levels with coronary artery disease and major adverse events at follow-up. Eur Heart J 26:137-144
24. 2 mass and activity with coronary artery calcification in young adults: the CARDIA Study. Arterioscl Thromb Vasc Biol 25:1-7
25. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E 2003 Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44:1381-1386
26. Arenillas JF, Alvarez-Sabin J, Molina CA, Chacon P, Montaner J, Rovira A, Ibarra B, Quintana M 2003 C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 34:2463-2468
27. 2 and C-reactive protein to incident stroke in middle-aged men and women: the Atherosclerosis Risk in Communities Study. Proc 5th Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, San Francisco, CA, 2004
28. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR 2003 Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34:623-631
29. Collins R, Armitage J, Parish S, Sleight P, Peto R 2004 Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
30. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, Ramires JA, Serrano Jr CV 2004 Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 177:161-166
31. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Maerz W 2004 Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89:1153-1159
32. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M 1999 Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209-216
33. Unno N, Nakamura T, Kaneko H, Uchiyama T, Yamamoto N, Sugatani J, Miwa M, Nakamura S 2000 Plasma platelet activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg 32:263-267
34. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA 2000 The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66:1522-1530
35. 2 and risk of myocardial infarction in the north and south of Europe. The HIFMECH Study Group. Atherosclerosis 168:283-288